Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab

• Status: Completed
• Trial end date: 2018-06-30
• Target enrollment: 0
• Participant gender: All

Summary

To determine the serum concentrations of ranibizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Treatments: Endothelial Growth Factors; Mitogens; Ranibizumab

Criteria

Inclusion Criteria:

• Infants with vascularly active ROP

• intravitreal ranibizumab

Exclusion Criteria:

• already accepted laser therapy